Search

Your search keyword '"Read, Robert C."' showing total 733 results

Search Constraints

Start Over You searched for: Author "Read, Robert C." Remove constraint Author: "Read, Robert C."
733 results on '"Read, Robert C."'

Search Results

1. Reactogenicity, immunogenicity and breakthrough infections following heterologous or fractional second dose COVID-19 vaccination in adolescents (Com-COV3): A randomised controlled trial

3. Persistence of immune responses after heterologous and homologous third COVID-19 vaccine dose schedules in the UK: eight-month analyses of the COV-BOOST trial

5. Antibiotics for lower respiratory tract infection in children presenting in primary care: ARTIC-PC RCT

9. Safety, tolerability and viral kinetics during SARS-CoV-2 human challenge in young adults

10. Effect of priming interval on reactogenicity, peak immunological response, and waning after homologous and heterologous COVID-19 vaccine schedules: exploratory analyses of Com-COV, a randomised control trial

12. Safety, immunogenicity, and reactogenicity of BNT162b2 and mRNA-1273 COVID-19 vaccines given as fourth-dose boosters following two doses of ChAdOx1 nCoV-19 or BNT162b2 and a third dose of BNT162b2 (COV-BOOST): a multicentre, blinded, phase 2, randomised trial

13. Persistence of immunogenicity after seven COVID-19 vaccines given as third dose boosters following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK: Three month analyses of the COV-BOOST trial.

14. Immunogenicity, safety, and reactogenicity of heterologous COVID-19 primary vaccination incorporating mRNA, viral-vector, and protein-adjuvant vaccines in the UK (Com-COV2): a single-blind, randomised, phase 2, non-inferiority trial

15. Distinct early cellular kinetics in participants protected against colonization upon Bordetella pertussis challenge

16. Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial

18. Antibiotics for lower respiratory tract infection in children presenting in primary care in England (ARTIC PC): a double-blind, randomised, placebo-controlled trial

19. Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial

24. Persistence of immune response in heterologous COVID vaccination schedules in the Com-COV2 study – A single-blind, randomised trial incorporating mRNA, viral-vector and protein-adjuvant vaccines

27. Corrigendum to “Persistence of immunogenicity after seven COVID-19 vaccines given as third dose boosters following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK: Three month analyses of the COV-BOOST trial” [J Infect 84(6) (2022) 795–813, 5511]

34. Effect of colonisation with Neisseria lactamica on cross-reactive anti-meningococcal B-cell responses: a randomised, controlled, human infection trial

38. Effect of priming interval on reactogenicity, peak immunological response, and waning after homologous and heterologous COVID-19 vaccine schedules: exploratory analyses of Com-COV, a randomised control trial

40. Effect of a quadrivalent meningococcal ACWY glycoconjugate or a serogroup B meningococcal vaccine on meningococcal carriage: an observer-blind, phase 3 randomised clinical trial

43. List of Contributors

46. Public attitudes to a human challenge study with SARS-CoV-2: a mixed-methods study

47. Safety, tolerability and viral kinetics during SARS-CoV-2 human challenge

48. Immunogenicity and Reactogenicity of BNT162b2 and mRNA1273 COVID-19 Vaccines Given as Fourth Dose Boosters in the COV-BOOST Randomised Trial Following Two Doses of ChAdOx1 nCov-19 or BNT162b2 and a Third Dose of BNT162b2

Catalog

Books, media, physical & digital resources